Client News

OKYO Pharma Limited: Appointment to Scientific Advisory Board
Home / Client News / OKYO Pharma Limited: Appointment to Scientific Advisory Board

London and New York, NY, February 23, 2023 OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the appointment of Jay S. Pepose, M.D., Ph.D., Founder and Medical Director of the Pepose Vision Institute and Professor of Clinical Ophthalmology at Washington University School of Medicine, to OKYO’s Scientific Advisory Board (SAB). In this role Dr. Pepose will help guide OKYO’s clinical programs for OK-101 for the treatment of DED. The Company anticipates opening its Phase 2 clinical trial of OK-101 to enrollment in the first quarter of 2023.

https://www.londonstockexchange.com/news-article/OKYO/appointment-to-scientific-advisory-board/15848249

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This